PTC's Votoplam Shows Dose-Dependent Slowing in Huntington's Disease Trial
Event summary
- PTC reported positive topline results from the 24-month interim analysis of the PIVOT-HD extension study, showing dose-dependent benefits in slowing disease progression for Stage 2 Huntington's disease patients.
- The 10 mg dose of votoplam demonstrated a 52% slowing of progression on the cUHDRS scale compared to a natural history cohort.
- Novartis has initiated the global Phase 3 INVEST-HD study, enrolling approximately 770 early-stage HD patients.
The big picture
PTC's positive data for votoplam comes as Huntington's disease remains an area of high unmet need with no approved therapies to slow progression. The initiation of a large, global Phase 3 trial by Novartis underscores the strategic importance of this asset in PTC's pipeline. The dose-dependent efficacy signals could position votoplam as a potential first-in-class treatment if subsequent trials succeed.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 INVEST-HD data will support accelerated approval for votoplam.
- Commercial Strategy
- How Novartis and PTC align on regulatory interactions and commercialization plans post-Phase 3.
- Execution Risk
- The pace at which Novartis can enroll and complete the Phase 3 study given its global scale.